Home » Newsletters » BioWorld Science

BioWorld Science

July 24, 2007

View Archived Issues

Novel treatment options for gastrointestinal disorders reported in recent patents

Novel diagnostic agents disclosed by Fujifilm, INSERM and Cedex

Amgen acquires Ilypsa and late-stage selective phosphate binder

Arena's phase I APD-791 trial for arterial thrombosis commences

Interim data from Bone Medical's phase II trial of Capsitonin capsules

DOR begins patient enrollment for phase II trial of orBec for acute GVHD prevention

Affiris commences phase I trial of Alzheimer's vaccine AD-01

EpiCept and Dalhousie University sign licensing agreement for EpiCept NP-1

Gilead Sciences reports results for the second quarter 2007

Low allergy symptom levels confound phase III PreHistin findings

Arpida acquires TLT Medical

Glenmark acquires CHR-1103 and CHR-1201

Mpex begins phase Ib multidose trial of MP-376 for CF

Positive interim results from Peplin's phase IIb study of PEP-005 for AK

EMEA approval of Genta's MAA for Genasense requires additional trial

Genzyme completes phase III trial of Mozobil for NHL

MedImmune initiates phase Ib trial of MEDI-545 for lupus

Abbott submits regulatory filings for lower-strength Kaletra/Aluvia tablet

Preclinical characterization of phase II antiinflammatory compound CJ-023423 from Pfizer

Positive opinion in Europe for smaller capsules of Tamiflu

First-in-human trial of MLN-8237 under way

Phase I/II trial of PMEG prodrug scheduled to begin this month

New analgesics disclosed in recent patent literature

Preclinical antiglaucomal efficacy of the novel prostanoid FP receptor agonist tafluprost presented

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...